10 employees
AmyPore develops an innovative drug that targets a common mechanism of Alzheimer's and Parkinson's diseases.
2018
$82K
from 2 investors over 2 rounds
AmyPore raised undisclosed on April 3, 2019
Investors: Incubateur inter-universitaire Impulse
AmyPore raised $82K on January 1, 2019
Investors: Executive Agency for Small and Medium-sized Enterprises (EASME)